Saturday 17 October 2026
Export ADVB’s income statement to Excel — free account
Advanced Biomed Inc.
ADVB Healthcare Diagnostics & Research
Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00. In the quarter to June 2026, EPS grew 54.8% and free cash flow fell 101.3%, each against the same quarter a year earlier.
3.98
0.90
−18.44%
Follow ADVB
| Jun '26 | Jun '25 | Jun '24 | |
|---|---|---|---|
P/E ratio |
0.90 | — | — |
P/S ratio |
0.00 | — | — |
Altman Z-Score |
0.68 | — | — |
P/FCF ratio |
0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
8.58 | — | — |
P/Operating CF |
(9.99) | — | — |
P/B ratio |
0.47 | — | — |
Price to Tangible BV |
0.48 | — | — |
EV/Sales |
0.00 | — | — |
EV/EBITDA |
0.00 | — | — |
EV/Operating CF |
(2.79) | — | — |
EV/FCF |
(1.20) | — | — |
Quick Ratio |
0.26 | 0.00 | 0.95 |
Current Ratio |
9.33 | 1.16 | 1.12 |
Net Debt/EBITDA |
0.06 | 0.03 | 1.22 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.00 | — |
Operating CF/Net income |
(0.29) | 1.79 | 0.76 |
Capex/Depreciation |
0.00 | (0.09) | (0.19) |
| 84.77% | (126.79%) | 0.00% | |
| 36.47% | (23.86%) | 0.00% | |
ROIC |
(32.76%) | (19.70%) | 0.00% |
Return on Tangible Assets |
54.39% | (93.79%) | (330.01%) |
Average Days of Receivables |
0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
4,985.27% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.03 |
Share Based Compensation of Revenue |
1,750.78% | — | — |
Graham Net Nets |
2.11 | — | — |
Graham Number |
33.69 | — | — |
Earnings Yield |
110.73% | — | — |
Free Cash Flow Yield |
(77.73%) | — | — |
Revenue per Share |
0.10 | 0.00 | 0.00 |
Operating CF per Share |
(1.55) | (5.68) | (2.13) |
Capex per Share |
(2.06) | (0.03) | (0.07) |
Free Cash Flow per Share |
(3.61) | (5.71) | (2.20) |
Cash per Share |
0.31 | 0.03 | 2.61 |
Shareholders Equity per Share |
9.80 | 3.39 | 1.66 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
9.80 | 3.39 | 1.66 |
Free Cash Flow |
(4.53) | (5.86) | (2.20) |
Working Capital |
12.28 | 3.14 | 0.32 |
Capital Expenditures |
(2.58) | (0.03) | (0.07) |
Net Current Asset Value |
12.28 | 3.00 | 0.25 |
EV/EBIT |
0.00 | — | — |
Capex to Sales |
20.23 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | — | — |
| Other line items | |||
Depreciation/Fixed assets |
— | 1.04 | 0.76 |
Cash ROIC |
(35.77%) | (166.92%) | (51.52%) |
Accounts Receivable Turnover |
0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Payables |
1.13 | 1.73 | — |
Average Assets |
18.31 | 13.66 | — |
Average Common Equity |
7.88 | 2.57 | — |
Columns are period end dates · fundamentals updated 15 Oct 2026